Transanal Total Mesorectal Excision Versus Laparoscopic TME for Rectal Cancer (NCT02252250) | Clinical Trial Compass
CompletedNot Applicable
Transanal Total Mesorectal Excision Versus Laparoscopic TME for Rectal Cancer
China70 participantsStarted 2014-10
Plain-language summary
To investigates the feasibility, practicability, safety and subjective as well as functional outcome of transanal minimal invasive surgery toal mesentery excision for rectal cancer.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Biopsy-proven adenocarcinoma of the rectum
* Eligible to undergo conventional laparoscopic low anterior resection or transanal hybrid-laparoscopic low anterior resection with or without a temporary diverting stoma
* Node negative (N0), T1 (high risk features), T2 and T3 rectal cancer on pelvic MRI
* Closest distance between tumor edge and mesorectal fascia 5mm or more based on pelvic MRI
* Rectal cancer located 3-10 cm from the anal verge
Exclusion Criteria:
* Metastasis
* Obstructing rectal cancer
* Synchronous colon cancer
* T4 rectal cancer not treated preoperatively with full-course chemoradiation
* Pregnant or breast-feeding
* Receiving any other study agents
* Fecal incontinence
* History of prior colorectal cancer
* History of inflammatory bowel disease
* History of pelvic radiation
* BMI \> 40
* Large uterine fibroids
* Uncontrolled intercurrent illness
What they're measuring
1
Adequacy of the total mesorectal excision(TME) based on standard guidelines on pathologic evaluation of TME specimens.